An exploratory, comparative case series of calcitonin gene-related peptide monoclonal antibodies in migraine patients with rosacea
Abstract
Rosacea is greater than 50% co-prevalent with migraines, and recent data as shown that Calcitonin Gene-Related Peptide (CGRP) is elevated in rosacea skin. CGRP monoclonal antibodies (MAbs) prevent migraine with known safety profiles, but their effect on rosacea is not known. This exploratory, retrospective study examines rosacea in patients with migraines, before and after CGRP MAbs. Of 13 eligible patients on stable/unchanged concurrent rosacea medications, the majority experienced improvement after CGRP MAbs. Mean rosacea severity scores for periods pre- and on-CGRP MAbs were, respectively, 1.19 [Standard Deviation (SD) 0.65], and 0.58, [SD 0.70], p=0.01. Prospective, placebo-controlled clinical trials are needed to further assess the utility of CGRP MAbs in rosacea.
How strong is the evidence?
Evidence Hub reads this as a case series, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health. Reported size: 13 participants or records.
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.